 |
Kyowa
Hakko in-licenses ARQ 197, an Anticancer Agent in Clinical Development,
From the US Company ArQule. (2007/04/27) |
|
Submission
of New Drug Application for Istradefylline(KW-6002), an Investigational
Anti-Parkinson's Disease Drug (2007/04/27) |
|
Application
for an Additional Indication of CombinationTherapy of Glufast and Insulin
Sensitizer in Japan (2007/04/23) |
|
A Once-weekly
Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent,
Was Approved (2007/04/18) |
|
Anti-Cancer
Agent Avastin, Approved in Japan (2007/04/18) |
|
Eisai Announces
Completion of Acquisition of Morphotek (2007/04/17) |
|
Eisai Withdraw
Application for Additional Indication of Aricept for Treatment of Severe
Alzheimer's Disease in Europe (2007/04/13) |
|
Shionogi
Announces Revisions to the Second Medium-Term Business Plan (2007/04/04) |
|
Santen Oy
Submits Marketing Approval for Glaucoma and Ocular Hypertension Drug Candidate
DE-085 (INN: Tafluprost) (2007/04/03) |
|
CanBas
and Takeda to Sign the Collaboration Agreementfor Investigational Compounds
for Treatment of Cancer (2007/03/30) |
|
LG Life
Sciences and Takeda Announce Collaboration for Anti-Obesity Drugs
(2007/03/30) |
|
Asahi Kasei
Pharma Corporation and Eisai Co., Ltd. Signed License Agreement for Vasodilator
Eril in Korea (2007/03/26) |
|
Eisai to
Acquire Morphotek (2007/03/22) |
|
Nippon Shinyaku
and Teva terminate HMN-214 License Agreement (2007/03/16) |
|
Shionogi
Concludes License Agreement with BioCryst Pharmaceuticals for Anti-Influenza
Drug Peramivir (2007/03/06) |
|
Eisai Establishes
New Manufacturing Subsidiary in United Kingdom (2007/03/05) |
|
GW and Otsuka
Announce Major Long Term Strategic Cannabinoid Alliance (2007/02/14) |
|
Eli Lilly
Japan and Shionogi to Co-Develop and Co-Market Duloxetine in Japan
(2007/02/02) |
|
Tanabe Seiyaku
Co., Ltd. and Mitsubishi Pharma Corporation Enter Into A Basic Agreement
to Merge on October 1, 2007 (2007/02/02) |
|
Proton
Pump Inhibitor Pariet Tablets 10mg Receives Approval in Japan for Helicobacter
Pylori Eradication (2007/01/30) |
|
Antiviral
Agent Copegus Tablet 200 mg Received Approval as a Combination Therapy
With Chronic Hepatitis C Treatment Drug Pegasys (2007/01/26) |
|
Anti TNF-α
Monoclonal Antibody Preparation REMICADE for Drip Infusion 100
Additional Indication of Treating Behcet’s Disease with Refractory Uveoretinitis
(2007/01/26) |
|
Eisai's
Inovelon Receives Marketing Authorization Approval From European Commission
(2007/01/22) |
|
Takeda Submits
an Application for an additionalIndication of Actosin Japan (2007/01/18) |
|
Marketing
Authorisation Granted to Takeda for Tandemact (pioglitazone/glimepiride)
for Type 2 Diabetes in Europe (2007/01/17) |
|
Nippon Shinyaku
and APOGEPHA Terminate an Agreement for the Development of an Agent for
Overactive Bladder (2007/01/16) |
|
Fujifilm
Acquires Problem Solving Concept, Inc., a Provider of Medical Imaging
Information Systems for Cardiology and Expands its Medical Imaging Business.
(2007/01/11) |
|
Daiichi Sankyo
Announces Filing of Supplemental New Drug Application for Welchol in the
Treatment of Type 2 Diabetes Mellitus (2007/01/05) |
|
Anti-Cancer
Agent, Herceptin Application for Approval of Additional Indication of
Operable Breast Cancer with HER2 Overexpression (2006/11/30) |
|
Daiichi
Sankyo, Inc. Announces Filing of New Drug Application for Amlodipine Besylate/Olmesartan
Medoxomil Combination for the Treatment of Hypertension (2006/11/29) |
|
Termination
of co-development agreements on HFT-290 (a tape for palliative care of
cancer pain) and NS-126 (an agent for allergic rhinitis and asthma)
(2006/11/24) |
|
Eisai
Announces Establishment of New Pharmaceuticals Marketing Subsidiary in
Portugal (2006/11/21) |
|
Nippon
Shinyaku Co., Ltd. and Pharmion Corporation Announce License Agreement
for Vidaza, an Agent for Myelodysplastic Syndromes (MDS) (2006/11/21) |
|
Eisai Recieves
Positive Opinion for Inovelon Marketing Authorization from European Committee
for Medicinal Products for Human Use (CHMP) (2006/11/20) |
|
Discontinuation
of Development of InvestigationalCompound TAK-128 for Peripheral Diabetic
Neuropathy (2006/11/02) |
|
ASKA Pharmaceutical,
Takeda Pharmaceutical Terminate License Agreement for Tavocept in Japan
(2006/11/02) |
|
Eisai
Launches New Rx-to-OTC Switch Product Higuard for Allergy-related Rhinitis
and Skin Problems (2006/10/31) |
|
PENTAX
launches sales of autofluorescence videoendoscope system in Japan
(2006/10/31) |
|
Shionogi
Discontinues Development of S-5751, a Prostaglandin D2 Receptor Antagonist
(2006/10/27) |
|
Ono Enters
into License Agreement with Sapphire Therapeutics, Inc. in Japan (2006/10/26) |
|
Eisai
Announces Completion of Acquisition of Four Oncology-Related Products
From Ligand (2006/10/26) |
|
Ultrasound
Contrast Medium Sonazoid Gets Import Approval (2006/10/26) |
|
Takeda and
BioNumerik Announce Termination of StrategicAlliance Agreement for Tavocept
for the U.S. and Canada (2006/10/24) |
|
Sanko Junyaku,
Eisai, and FUJIREBIO Sign Joint Research Agreement for Development of
a New KL-6 Test Kit (2006/10/19) |
|
U.S. FDA
Approves Aricept For Treatment of Severe Alzheimer's Disease (2006/10/14) |
|
Eisai Receives
Decisions of Summary Judgment Motion in US Legal Action Over Aciphex ANDA
Filing (2006/10/09) |
|
Xenon and Takeda Announce Agreement To Develop and Commercialize XEN401 for Pain in Japan and Certain Asian Countries (2006/10/03) |
|
Eisai's research subsidiary “KAN Research Institute” launches research operations in The Kobe Medical Industry Development Project Site (2006/10/02) |
|
Chugai Pharmaceutical to Establish an Oncology Unit (2006/09/27) |
|
Eisai's Lawsuit Against Three Japanese Generic Drug Manufacturers/Distributors Regarding the Sales of Selbex Based on the Japanese Unfair Competition Prevention Law Dismissed by Court (2006/09/27) |
|
Novartis Pharma K.K., Daiichi Sankyo Co., Ltd. Agree to Terminate the Contract Concerning OTC Medicine (2006/09/19) |
|
Co-Development and Co-Marketing Agreement Secured for the Antiresorptive Bisphosphonate R484 (2006/09/12) |
|
DAIICHI SANKYO to Transfer All Daiichi Pure Chemicals Shares (2006/09/11) |
|
Fujifilm acquires all shares of Daiichi Radioisotope Laboratories (2006/09/11) |
|
Eisai Acquires Four Oncology-Related Products from Ligand (2006/09/08) |
|
Ajinomoto and Sankyo Reach Agreement on the Development, Manufacture and Marketing of the New Diabetes Drug, AJD101 (2006/08/31) |
|
Olympus Increases Investment in Cytori Therapeutics (2006/08/23) |
|
Janssen Pharmaceutical, Tanabe Seiyaku Co-Develop and Co-market of the Anti TNFα Monoclonal Antibody Preparation “CNTO148”(Golimumab) (2006/08/21) |
|
GlaxoSmithKline and Shionogi Complete Initial Clinical Study for HIV Integrase Inhhibitor (2006/08/15) |
|
Crestor for the treatment of hypercholesterolemia-The analysis from the interim report of post-marketing surveillance submitted to the regulatory authority (2006/08/07) |
|
Eisai Commences U.S. Legal Action over Aricept ODT ANDA Filing (2006/08/04) |
|
Marketing Authorisation Granted for Competact (pioglitazone/metformin) for Type 2 Diabetes in Europe (2006/08/03) |
|
Sales of Antihypertensive Agent Olmetec Begin in China (2006/08/02) |
|
Daiichi Pharmaceutical to Develop and Market Anti-EGFr Drug Nimotuzumab in Japan (2006/08/01) |
|
Allowance of an investigational new drug application (IND) for ONO-4538 / MDX-1106, a fully human anti-PD-1 antibody (2006/08/01) |
|
Eisai Starts Marketing Severe Chronic Pain Agent Prialt in the UK and Germany (2006/07/31) |
|
Co-development and Distribution Agreement on treatment for pancreatic exocrine insufficiency (SA-001) in Japan concluded (2006/07/27) |
|
Santen’s Global Development: Creating New Drug Candidates and Generating Growth in Promising Regions by Leveraging Strengths (2006/07/25) |
|
Olympus Acquires Single Molecule Fluorescence Spectroscopy Technology and IP Portfolio from Evotec (2006/07/24) |
|
Start of Phase 3 Clinical Program in the U.S.of Fixed Dose Combination Product of Actos + TAK-536for Treatment of Patientswith Type 2 Diabetes Associated with Hypertension (2006/07/24) |
|
Olympus enters global immunoassay market―Expanding the diagnostic business through clinical chemistry system synergies (2006/07/21) |
|
To Enhance Tanabe’s RA Product Portfolio Launch of Anti-Rheumatic, “Methotrexate tablets 2mg TANABE” (2006/07/20) |
|
Astellas Discontinues Development of Alzheimer’s Disease Compound FK962 (2006/07/18) |
|
Eisai and Teva Mutually Agree To End Collaboration Agreement for Rasagiline (2006/07/12) |
|
Takeda and Galaxy Biotech Sign License Agreement for Galaxy's Investigational Antibodies for the Treatment of Cancer (2006/07/10) |
|
Ono Pharmaceutical Co., Ltd. , Astellas Pharma Inc. File Application for the Osteoporosis Treatment ONO-5920/YM529 in Japan (2006/07/10) |
|
Shionogi to Launch Non-pyrazolone Antipyretic Analgesic “SedesRV” with Vitamin B1 for Headaches and Pain Due to Stiffness of the Neck, and Fever (2006/07/07) |
|
Pentax Announces Airway Scope AWS-S100, Rigid Video Laryngoscope for Intubation (2006/07/06) |
|
Pharmaceutical Marketing Subsidiary in Singapore Launches Operations (2006/07/04) |
|
Application for Approval of Additional Indication for Type 2 Diabetic Nephropathy for “Micaardis,” Angiotensin II Receptor Blocker, Is Filed (2006/07/03) |
|
Eisai Licenses Selective Estrogen Receptor Modulators (SERMs) to Radius (2006/06/29) |
|
Takeda to Establish a New Company for European Sales & Marketing (2006/06/27) |
